It has become clear that abrogating aberrant FGFR signalling in urothelial cancer (driven by FGFR3 mutations) and cholangiocarcinoma (driven by FGFR2 fusions) has led to improved clinical outcomes in these molecularly defined patient populations. Here, FGFR3 is linked to cholangiocarcinoma.